Flow Cytometric Measurement of ABO Antibodies in ABO-Incompatible Living Donor Kidney Transplantation
Authors:
- Piero V. ValliPVPiero V. Valli
- Astrid StarkeASAstrid Starke
- Regula J. MuellerRMRegula J. Mueller
- Thomas FehrTFThomas Fehr
- Marija Cesar-ÖzpamirMCMarija Cesar-Özpamir
- Urs SchanzUSUrs Schanz
- Markus WeberMWMarkus Weber
- Rudolf P. WüthrichRWRudolf P. Wüthrich
- Jörg D. SeebachJSJörg D. Seebach
- Georg StussiGSGeorg Stussi
- 27 December 2007
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 84 (12S) , S20-S23
Abstract
Due to different detection methods, a comparison of anti-A/B antibody (Ab) levels among transplantation centers after living donor ABO-incompatible kidney transplantation is problematic. In the present study, anti-A/B Ab levels were determined prior to, and after, blood group A-to-O kidney transplantation using a recently established semiquantitative flow cytometry-based method, ABO fluorescence-activated cell sorting (ABO-FACS), and compared with standard agglutination titers and indirect antiglobulin testing. Pretransplant agglutination titers were reduced from 1:64 to 1:4, by a total of 14 Glycosorb A column immunoadsorptions (IADSs). Compared with the agglutination titers, antidonor immunoglobulin (Ig) M ABO-FACS mean fluorescence intensity ratios (MFIRs) decreased faster and remained low. No difference was observed using donor type or third-party A red blood cells (RBCs) for the ABO-FACS. Glycosorb A columns were not specific, also reducing anti-B and antiporcine IgM levels, which was confirmed by detecting anti-A/B and antiporcine Abs in the column eluates. In conclusion, analysis of pre- and posttransplant Abs from ABO-incompatible kidney transplant recipients by ABO-FACS allows a better understanding of Ab kinetics, which may improve the design of future IADS protocols.Keywords
This publication has 16 references indexed in Scilit:
- ABO blood group and related antigens, natural antibodies and transplantationTissue Antigens, 2006
- ABO‐incompatible allotransplantation as a basis for clinical xenotransplantationXenotransplantation, 2006
- Xenotransplantation and ABO incompatible transplantation: The similarities they shareTransfusion and Apheresis Science, 2006
- ABO‐incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti‐CD20 antibody treatmentXenotransplantation, 2006
- Present status of ABO‐incompatible kidney transplantation in JapanXenotransplantation, 2006
- ABO Incompatible High‐Titer Renal Transplantation without Splenectomy or Anti‐CD20 TreatmentAmerican Journal of Transplantation, 2005
- ABO Incompatible Kidney Transplantations Without Splenectomy, Using Antigen-Specific Immunoadsorption and RituximabAmerican Journal of Transplantation, 2005
- Plasmapheresis, CMV Hyperimmune Globulin, and Anti-CD20 Allow ABO-Incompatible Renal Transplantation Without SplenectomyAmerican Journal of Transplantation, 2004
- Excellent Long-term Outcome of ABO-Incompatible Living Donor Kidney Transplantation in JapanAmerican Journal of Transplantation, 2004
- Plasma exchange conditioning for ABO‐incompatible renal transplantationJournal of Clinical Apheresis, 2004